Dzherelo is now classified under complementary medicines category by MCC of the Department of Health, in South Africa. Moreover, this drug was recently approved in Mongolia.
Immunoxel is the improved version of Dzherelo. This drug has been shown to be safe and effective in a variety of clinical conditions including seasonal flu, influenza, acute respiratory infections, tuberculosis, hepatitis, HIV, autoimmune conditions, and malignancies.
However, conventional Tuberculosis (TB) chemotherapy success rates are significantly lower in patients with Multi Drug and Resistant (MDR) and Extensively Drug Resistant TB (XDR-TB) and surveys indicating 10 percent of MDR-TB cases were XDR-TB.
Current treatment of drug resistant TB can take up to 18-24 months. No new classes of anti-TB drugs were introduced in the past 40 years and existing drugs are practically useless against drug-resistant TB.
Mr. Volodymyr Pylypchuk, Director, Ekomed, said: South Africa is burdened by one of the worst tuberculosis and HIV epidemics in the world. Our commercial partner Zodiac Capital has been working diligently and we are very excited to announce that that their effort paid off. Our Immunoxel works through completely novel immune mechanism and to the best of our knowledge is the only and most effective adjuvant to TB and AIDS drugs. The approach that we have developed drastically shortens treatment duration and can save countless lives right now. Our clinical studies conducted in Ukraine during last ten years have shown convincingly that we can offer reliable, cost-effective solution to the global TB and HIV crisis.”